

I\_136\_0239-2

136th General Assembly  
Regular Session  
2025-2026

Sub. H. B. No. 12

---

To enact section 3792.08 of the Revised Code  
regarding prescribing, dispensing, and  
administering drugs and to name this act the  
Jeff, Dave, and Angie Patient Right to Try Act.

1  
2  
3  
4

**BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:**

**Section 1.** That section 3792.08 of the Revised Code be  
enacted to read as follows:

5  
6

**Sec. 3792.08.** (A) As used in this section:

7

(1) "Health-related licensing board" has the same meaning  
as in section 3719.062 of the Revised Code.

8  
9

(2) "Hospital" has the same meaning as in section 3722.01  
of the Revised Code and includes a hospital owned or operated by  
the United States department of veterans affairs.

10  
11  
12

(3) "In-house physician" means a physician who is employed  
or contracted by the hospital or inpatient facility where a  
patient is being treated, or who has hospital privileges at the  
hospital where a patient is being treated.

13  
14  
15  
16

(4) "Inpatient facility" means either or both of the

17



mxmash3t9opgu6dlhcgvet

following: 18

(a) A skilled nursing facility as defined in section 19  
5165.01 of the Revised Code; 20

(b) A freestanding inpatient rehabilitation facility 21  
licensed under section 3702.30 of the Revised Code. 22

(5) "Off-label use" means the use of a drug that meets 23  
both of the following: 24

(a) The drug is approved by the United States food and 25  
drug administration to treat or prevent a disease, illness, or 26  
infection, but prescribed for or used by a patient to treat or 27  
prevent another disease, illness, or infection. 28

(b) The drug is legal for use in this state. 29

(6) "Patient's personal representative" has the same 30  
meaning as in section 3701.74 of the Revised Code. 31

(7) "Pharmacist" means an individual who holds a license 32  
issued under section 4729.08 of the Revised Code authorizing the 33  
individual to practice pharmacy. 34

(8) "Physician" means an individual licensed under Chapter 35  
4731. of the Revised Code to practice medicine and surgery, 36  
osteopathic medicine and surgery, or podiatric medicine and 37  
surgery. 38

(9) "State agency" means any organized agency, board, 39  
body, commission, department, institution, office, or other 40  
entity established by the laws of the state for the exercise of 41  
any function of state government. "State agency" does not 42  
include a court. 43

(B) (1) A pharmacist shall dispense, and a hospital, 44

inpatient facility, outpatient health care facility, or pharmacy  
shall allow the dispensing of a drug, including for off-label  
use, prescribed by a physician, to a patient except in either of  
the following circumstances:

(a) As provided in section 4743.10 of the Revised Code,  
the pharmacist, hospital, inpatient facility, outpatient health  
care facility, or pharmacy has a moral, ethical, or religious  
belief or conviction that conflicts with the drug's dispensing.

(b) The pharmacist has documented that the patient has a  
history of a life-threatening allergic reaction to the  
prescribed drug, there is a life-threatening contraindication or  
life-threatening drug interaction for that patient, or the drug  
has a high probability of causing serious disability or serious  
injury to that patient.

(2) When neither exception in division (B)(1)(a) or (b) of  
this section applies and a pharmacist must dispense, or a  
hospital, inpatient facility, outpatient health care facility,  
or pharmacy must allow the dispensing of, a drug, including for  
off-label use, for a patient pursuant to this section, but the  
pharmacist, hospital, inpatient facility, outpatient health care  
facility, or pharmacy has an objective, good faith, and  
scientific objection to the administration or dosage of the drug  
for that patient or that patient's condition, then after  
explaining and discussing the objection with the physician, if  
it is still the clinical judgment of the physician to dispense  
the drug, the pharmacist, hospital, inpatient facility,  
outpatient health care facility, or pharmacy shall dispense the  
drug and shall be immune from civil liability, professional  
discipline, and sanctions or fines imposed by a regulatory  
authority for any harm that may arise from the dispensing or

administration of the drug starting from the date of dispensing 75  
if the pharmacist, hospital, inpatient facility, outpatient 76  
health care facility, or pharmacy meets the following minimum 77  
requirements: 78

(a) Documents in the patient's medical record that the 79  
objective, good faith, and scientific objection was discussed 80  
with the physician and notes the date of the discussion. The 81  
objection is not required to be described in detail. 82

(b) Documents the objective, good faith, and scientific 83  
objection within twenty-four hours of dispensing the drug. 84

(3) Nothing in this section prevents compliance with 85  
federal laws or laws of this state governing the practice of 86  
pharmacy and the dispensing or administration of drugs, but it 87  
establishes that the final decision on whether a prescribed drug 88  
is dispensed pursuant to division (B)(1) of this section shall 89  
be made by the physician. 90

(4) In the case of a pharmacist who practices within a 91  
hospital's or inpatient facility's pharmacy and where an in- 92  
house physician issues a prescription for a drug, including for 93  
off-label use, that is neither in stock nor listed on the 94  
hospital's or facility's formulary, and the patient can obtain 95  
the drug at an outpatient pharmacy, then the hospital or 96  
inpatient facility must permit the drug to be brought into the 97  
hospital or inpatient facility to be identified for the 98  
patient's use. To be identified for the patient's use, the 99  
hospital or inpatient facility must determine that the drug was 100  
prescribed for the patient, is in the original manufacturer's 101  
packaging or is labeled from an outpatient retail pharmacy for 102  
the patient, has been approved by the physician for the 103  
patient's use, and is not outside of its beyond-use or 104

expiration date. If the drug is able to be identified according 105  
to the hospital or inpatient facility's drug identification 106  
procedure, then the drug shall be administered to the patient in 107  
the hospital or inpatient facility. 108

(5) When a hospital or inpatient facility patient or a 109  
patient's personal representative wishes to try a drug to treat 110  
a patient's condition, but there is no in-house physician 111  
willing to prescribe the drug, the hospital or inpatient 112  
facility shall not obstruct or intentionally delay the transfer 113  
of that patient to another hospital, inpatient facility, or 114  
hospice that is willing to accept and treat the patient, nor 115  
shall the hospital or inpatient facility prevent the patient's 116  
discharge if that is the wish of the patient or the patient's 117  
personal representative. 118

(6) When there is a safety concern regarding a 119  
prescription for a drug, including a drug for off-label use, a 120  
pharmacist should discuss any prescription dosage 121  
recommendations or other clinical concerns with the physician, 122  
the patient, or the patient's personal representative. There 123  
should be risk-benefit discussions between the physician, the 124  
patient or the patient's personal representative, and other 125  
inpatient and outpatient medical staff directly involved in the 126  
patient's care. The ultimate decision to take a drug prescribed 127  
by the physician shall be made by the consenting patient or the 128  
patient's personal representative. 129

(C) In an outpatient pharmacy setting, if a drug is not 130  
covered by a patient's health benefit plan or the patient does 131  
not want to wait for prior authorization, the physician or 132  
pharmacist shall notify the patient of the option to pay for the 133  
drug out of pocket. The physician or pharmacist must notify the 134

patient of the estimated out-of-pocket costs for the drug, and 135  
the pharmacist must offer the drug at an upfront, out-of-pocket 136  
cost to the patient. 137

(D) Except as provided in division (F) of this section, a 138  
health-related licensing board, the department of health, or 139  
another state agency responsible for the licensure or regulation 140  
of health care professionals or health care facilities shall not 141  
consider the action of prescribing, dispensing, or administering 142  
a drug to a consenting patient or with the consent of the 143  
patient's personal representative, including for off-label use, 144  
by a physician, pharmacist, hospital, inpatient facility, 145  
outpatient health care facility, or pharmacy under this section 146  
to be unlawful, unethical, unauthorized, or unprofessional 147  
conduct and shall not pursue professional discipline or fines or 148  
other regulatory sanctions against the physician, pharmacist, 149  
hospital, facility, or pharmacy except in cases where a court 150  
has determined that the prescribing, dispensing, or 151  
administering of the drug to that patient was done with 152  
recklessness or gross negligence. This section does not provide 153  
a physician immunity from civil liability. Except as provided in 154  
division (B) (2) of this section, this section does not provide a 155  
pharmacist, hospital, inpatient facility, outpatient health care 156  
facility, or pharmacy immunity from civil liability. 157

(E) A health care professional should be free to engage 158  
in scientific debate. A health-related licensing board, the 159  
department of health, or other state agency responsible for the 160  
licensure or regulation of health care professionals shall not 161  
pursue or threaten to pursue professional discipline or fines or 162  
other regulatory sanctions against a physician, pharmacist, or 163  
other licensed health care professional for doing either of the 164  
following: 165

(1) Publicly expressing an opinion regarding the safety, 166  
risks, benefits, or efficacy of a drug approved or authorized by 167  
the United States food and drug administration, including a drug 168  
prescribed for off-label use, or other medical intervention 169  
because that opinion does not align with the opinions of the 170  
board, department, other state agency, a board of health of a 171  
city or general health district, or other health authority. 172

(2) Informing a patient of safety concerns or risks that 173  
may be associated with a drug or other medical intervention. 174

This division does not provide a health care professional 175  
immunity from civil liability to a patient under the health care 176  
professional's care in a private care setting. 177

(F) Except for division (E) of this section, no portion of 178  
this section applies to, repeals, or supersedes existing law 179  
regarding prescribing, dispensing, or administering any of the 180  
following: 181

(1) Controlled substances, including opioids; 182

(2) Drugs subject to a United States food and drug 183  
administration risk evaluation and mitigation strategy; 184

(3) Cross-sex hormones or puberty-blocking drugs, as 185  
defined in section 3129.01 of the Revised Code, to be used in 186  
violation of section 3129.02 of the Revised Code; 187

(4) Abortifacients when prescribed, dispensed, or 188  
administered to patients who are believed to be pregnant; 189

(5) Drugs that are known to be used for the intent or 190  
purpose of euthanasia. 191

**Section 2.** This act shall be known as the Jeff, Dave, and 192  
Angie Patient Right to Try Act. 193